Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$114.51

6.205 (5.73%)

, INTC

Intel

$45.30

-0.21 (-0.46%)

09:55
01/26/18
01/26
09:55
01/26/18
09:55

Early notable gainers among liquid option names on January 26th

Notable gainers among liquid option names this morning include AbbVie (ABBV) $117.59 +9.22, Intel (INTC) $48.71 +3.41, Arthur J. Gallagher (AJG) $69.45 +3.80, Gilead (GILD) $83.96 +2.77, and Biogen (BIIB) $365.10 +10.98.

ABBV

AbbVie

$114.51

6.205 (5.73%)

INTC

Intel

$45.30

-0.21 (-0.46%)

AJG

Arthur J. Gallagher

$68.65

2.995 (4.56%)

GILD

Gilead

$81.19

-0.11 (-0.14%)

BIIB

Biogen

$353.74

7.24 (2.09%)

  • 26

    Jan

  • 06

    Feb

  • 12

    Feb

  • 16

    Feb

  • 08

    Mar

  • 30

    May

ABBV AbbVie
$114.51

6.205 (5.73%)

01/04/18
JEFF
01/04/18
NO CHANGE
Target $120
JEFF
Buy
Jefferies calls AbbVie top pick in Pharma, ups target to $120
Jefferies analyst Jeffrey Holford raised his price target for AbbVie to $120 from $115 and says the stock is his top pick in U.S. Large Cap Pharma. Positive estimate revisions tied to tax reform, the Mavyret launch and share repurchases put the company "in a strong position" to beat and raise through 2018, Holford tells investors in a research note. He believes the company's 2018 guidance is likely too conservative.
01/02/18
PIPR
01/02/18
NO CHANGE
PIPR
Overweight
AbbVie joining peers with typical January price hikes, says Piper Jaffray
Piper Jaffray analyst Richard Purkiss noted that AbbVie (ABBV) took early-January price increases, highlighting that Humira saw a 9.7% increase that is similar in both timing and magnitude to last year's increase and once again "exactly" matches Amgen's (AMGN) Enbrel. In a note of his own earlier this morning titled "'Tis the Season; Price Increases Continue Like Clockwork for Many Biotech Drugs," Piper Jaffray analyst Christopher Raymond highlighted that Amgen and Biogen (BIIB) also increased prices on a number of important franchise products effective January 1, 2018. Purkiss maintains his Overweight rating on AbbVie shares.
01/02/18
RBCM
01/02/18
DOWNGRADE
RBCM
Sector Perform
Enanta downgraded to Sector Perform at RBC Capital after 'considerable run'
As reported earlier, RBC Capital analyst Brian Abrahams downgraded Enanta (ENTA) to Sector Perform from Outperform, saying his positive near-term thesis on Mavyret has now played out and the potential for long-term royalties from AbbVie (ABBV) are "baked into the stock". The analyst believes that the trajectory of the treatment is now better appreciated" by the Street, adding the stock is more likely to trade in line in the immediate term given the "limited patient data for the NASH/PBC and RSV programs in 2018".
12/29/17
PIPR
12/29/17
NO CHANGE
PIPR
Biotech fund outflows continue, says Piper Jaffray
For the weekly period ending Wednesday, December 27, healthcare/biotech funds saw $338M in net outflows, representing a 0.58% decrease in assets, Piper Jaffray analyst Christopher Raymond tells investors in a research note. This marks the seventh straight negative week and the eleventh week of outflows in the past 12 weeks, the analyst points out in a research note titled "Ending 2017 on a Down Note: Biotech Outflows Continue."
INTC Intel
$45.30

-0.21 (-0.46%)

01/26/18
MKMP
01/26/18
NO CHANGE
Target $55
MKMP
Buy
Intel price target raised to $55 from $50 at MKM Partners
MKM Partners analyst Ruben Roy raised his price target on Intel to $55 and kept his Buy rating after Q4 earnings. Roy says the company continues to highlight the data-centric portion of its business as it diversifies away from the PC market, which drive Intel to faster longer-term revenue growth at stronger profitability margins. The analyst expects the multiples to follow, noting that the current valuation appears attractive while raising his FY18 EPS view to $3.55 from $3.25.
01/26/18
BARD
01/26/18
NO CHANGE
Target $60
BARD
Outperform
Intel price target raised to $60, added as top idea at Baird
Intel analyst Tristan Gerra raised his price target on Intel to $60 from $50 and added it as a top idea following the company's better than expected Q4 results. The analyst cited its continued revenue growth and operating margins profile while redistributing its cash. He said some of the upcoming catalysts include AI, 3D NAND, 5G modems, and FGPA's in data centers. Gerra reiterated his Outperform rating on Intel shares.
01/26/18
STFL
01/26/18
NO CHANGE
STFL
Intel demand comments have positve read for Micron, Smart Global, says Stifel
Stifel analyst Kevin Cassidy said the strong demand reported by Intel (INTC), particularly in data center and NAND Flash, are positive for Micron (MU) and Smart Global (SGH). Additionally, customers buying high performance processors benefits interconnect companies such as Mellanox (MLNX), said Cassidy. Intel management also noted strength in the commercial gaming business, which could benefit Nvidia (NVDA) and AMD (AMD), the analyst added.
01/26/18
NEED
01/26/18
NO CHANGE
Target $50
NEED
Buy
Intel price target raised to $50 from $45 at Needham
Needham analyst N. Quinn Bolton raised his price target on Intel to $50 and kept his Buy rating after a Q4 earnings beat and Q1 outlook. Bolton notes that Data Center Group revenue topped expectations for the 2nd straight quarter on strength in Cloud and Enterprise amid the company transition to a data-centric business. The analyst also notes "major" benefits from the U.S. tax changes lowering its effective rate to 14% from 22%-23%.
AJG Arthur J. Gallagher
$68.65

2.995 (4.56%)

01/26/18
RHCO
01/26/18
NO CHANGE
Target $75
RHCO
Buy
Arthur J. Gallagher price target raised to $75 from $70 at SunTrust
SunTrust analyst Mark Hughes raised his price target on Arthur J. Gallagher to $75 and kept his Buy rating after a Q4 earnings beat, citing "slightly faster Brokerage organic growth" as well as positive momentum in pricing and exposures in its core P&C Brokerage business. Hughes adds that the company's valuation is "attractive".
12/13/17
RHCO
12/13/17
NO CHANGE
Target $70
RHCO
Buy
Arthur J. Gallagher has positive growth prospects, says SunTrust
SunTrust analyst Mark Hughes kept his Buy rating and a $70 price target on Arthur J. Gallagher (AJG) after the company's analyst day. Hughes says the management was upbeat on the prospects for property & casualty rates experiencing 20-25% increase in policy renewals, as well as brokerage organic growth, to improve next year. The analyst notes that commentary on the Wholesale segment was particularly positive, which could also benefit James River (JRVR) and Kinsale (KNSL).
10/04/17
DBAB
10/04/17
DOWNGRADE
Target $64
DBAB
Hold
Arthur J. Gallagher downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Joshua Shanker downgraded Arthur J. Gallagher (AJG) to Hold with an unchanged price target of $64 citing valuation following the recent share rally. Recent appreciation of the insurance brokerage stocks has not come with an increase in earnings outlooks, Shanker tells investors in a research note. The analyst this morning also downgraded Marsh & McLennan (MMC).
05/02/17
05/02/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AMD (AMD) downgraded to Underperform from Neutral at Macquarie with analyst Srini Pajjuri telling investors PC progress was disappointing versus high expectations and margin expansion will be difficult. 2. CNA Financial (CNA) downgraded to Hold from Buy at Deutsche Bank with analyst Joshua Shanker citing valuation with the stock up 56% over the past 12 months. The analyst raised his price target for the shares to $46 from $45 following CNA's first quarter results. 3. Arthur J. Gallagher (AJG) downgraded to Market Perform on valuation at Raymond James with analyst Gregory Peters citing valuation. 4. Ocwen (OCN) downgraded to Neutral on valuation at Compass Point with analyst Fred Small citing the over 40% jump in shares following the announcement of a strategic deal with New Residential (NRZ) on Monday. The analyst maintained a $3.50 price target on Ocwen shares and recommends moving to the sidelines until viability into long-term earnings power emerges. 5. Cerner (CERN) downgraded to Neutral from Buy at Hilliard Lyons with analyst Stephen Turner citing price appreciation and raised its price target to $68. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GILD Gilead
$81.19

-0.11 (-0.14%)

01/22/18
JEFF
01/22/18
NO CHANGE
Target $125
JEFF
Buy
Celgene, Juno deal 'smart' if more than JCAR017 plays out, says Jefferies
Following the announced acquisition of Juno Therapeutics (JUNO) by Celgene (CELG), Jefferies analyst Michael Yee notes that in the short term, the Street will debate whether pivotal Juno data coming will look better than Kite's (GILD) Yescarta and whether JCAR17 is truly differentiated. Longer-term, the analyst believes this is a deal hinged on Celgene's confidence in going "all in" on cell therapy over the next 5-10 years. Like Gilead/Kite, this will be a "smart deal" if more than just JCAR17 plays out, he contends, adding that he thinks it will over next few years. Yee reiterates a Buy rating and $125 price target on Celgene's shares.
01/16/18
SBSH
01/16/18
NO CHANGE
SBSH
Buy
Juno could be worth $110 per share in takeover, says Citi
After the Wall Street Journal reported tonight that Celgene (CELG) is in talks to acquire Juno Therapeutics (JUNO), Citi analyst Robyn Karnauskas says her analysis indicates Juno could be worth $110 per share in a takeover. The stock in after-hours trading jumped 43%, or $19.50, to $65.10. The analyst, however, points that Kite Pharma had more data at the time of acquisition and was acquired by Gilead Sciences (GILD) for an aggregate price of $11.9B. Karnauskas also notes that Celgene already downs 25% of June's revenues.
01/16/18
WELS
01/16/18
UPGRADE
Target $96
WELS
Outperform
Gilead upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Jim Birchenough upgraded Gilead Sciences to Outperform and raised his price target for the shares to $96 from $84. Following management's update last week at a conference, the analyst expects more stable hepatitis C virus trends in 2018, "trough earnings" in 2019, and multiple expansion on growth beyond 2019.
01/26/18
JEFF
01/26/18
UPGRADE
Target $95
JEFF
Buy
Gilead upgraded to Buy from Hold at Jefferies
Jefferies analyst Michael Yee upgraded Gilead Sciences to Buy and raised his price target for the shares to $95 from $87. The drugmaker closed yesterday down 11c to $81.19. Gilead "has had it tough since 2015," but he worst is "generally moving behind them," Yee tells investors in a research note. The analyst sees consensus earnings re-growing in 2020 and beyond and three years of declining. He wants to own the stock coming out of the decline and back into the recovery period. Gilead's upcoming 2018 guidance will likely be low for its hepatitis C virus business, and this should not be surprising, Yee contends. At around $80, the analyst thinks the stock's risk/reward "looks good" with upside to $90-$100 if the business stabilizes and the new pipeline plays out to 2019 and beyond.
BIIB Biogen
$353.74

7.24 (2.09%)

01/26/18
HCWC
01/26/18
NO CHANGE
Target $363
HCWC
Buy
Biogen price target raised to $363 from $340 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised his price target for Biogen to $363 and reiterates a Buy rating on the shares following yesterday's Q4 results.
01/26/18
RBCM
01/26/18
NO CHANGE
Target $347
RBCM
Sector Perform
Biogen price target raised to $347 from $321 at RBC Capital
RBC Capital analyst Brian Abrahams raised his price target on Biogen to $347 and kept his Sector Perform rating after Q4 earnings. The analyst says Biogen is a "safe" large cap for 2018 based on its latest stronger-than-expected ex-U.S. Spinraza growth and good MS resilience, but believes the company needs to diversify revenues in the long-term, adding that risk-reward at current levels is balanced.
01/26/18
RHCO
01/26/18
NO CHANGE
Target $392
RHCO
Buy
Biogen price target raised to $392 from $354 at SunTrust
SunTrust analyst Yatin Suneja raised his price target on Biogen to $392 and kept his Buy rating after above-consensus Q4 sales driven by solid performance across business units. Suneja says Sprinza, Biosimilars, and the anti-CD20 franchise will continue to deliver growth to the overall business ahead of the key value inflection Alzheimer's data in late 2019.
01/26/18
DBAB
01/26/18
NO CHANGE
Target $373
DBAB
Buy
Biogen price target raised to $373 from $358 at Deutsche Bank
Deutsche Bank analyst Andrew Peters raised his price target for Biogen to $373 saying the multiple sclerosis franchise continues to show resiliency. While yesterday's Q4 results and initial 2018 financial guidance suggest continued resilience of the core MS franchise and further strength of the Spinraza launch, investor focus for the remainder of 2018 will be on potential capital allocation decisions, Peters tells investors in a post-earnings research note. The analyst views the quarter as a "good start to the year" and reiterates a Buy rating on Biogen.

TODAY'S FREE FLY STORIES

GE

General Electric

$13.99

0.33 (2.42%)

06:32
04/20/18
04/20
06:32
04/20/18
06:32
Earnings
Breaking Earnings news story on General Electric »

General Electric reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 25

    Apr

HON

Honeywell

$148.36

-1.035 (-0.69%)

06:32
04/20/18
04/20
06:32
04/20/18
06:32
Earnings
Honeywell reports Q1 EPS ex-items $1.95, consensus $1.91 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 03

    May

  • 25

    Jun

SYF

Synchrony

$35.35

0.46 (1.32%)

06:32
04/20/18
04/20
06:32
04/20/18
06:32
Hot Stocks
Synchrony reports Q1 net interest margin 16.05% »

Return on assets was 2.7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 30

    May

FB

Facebook

$168.11

1.73 (1.04%)

06:31
04/20/18
04/20
06:31
04/20/18
06:31
Periodicals
Auditor clears Facebook despite Cambridge Analytica leak, WSJ reports »

PricewaterhouseCoopers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

CFG

Citizens Financial

$41.86

0.84 (2.05%)

06:31
04/20/18
04/20
06:31
04/20/18
06:31
Earnings
Citizens Financial reports Q1 EPS 78c, consensus 76c »

Reports Q1 revenue $1.5B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 20

    Jul

  • 19

    Oct

SYF

Synchrony

$35.35

0.46 (1.32%)

06:31
04/20/18
04/20
06:31
04/20/18
06:31
Earnings
Breaking Earnings news story on Synchrony »

Synchrony reports Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 30

    May

UDN

PowerShares DB US Dollar Index Down

06:31
04/20/18
04/20
06:31
04/20/18
06:31
Technical Analysis
PowerShares DB US Dollar Index Down: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$172.79

-5.05 (-2.84%)

, LPL

LG Display

$11.71

-0.325 (-2.70%)

06:30
04/20/18
04/20
06:30
04/20/18
06:30
Periodicals
Apple hits a snag in diversification of screen suppliers, WSJ says »

According to the Wall…

AAPL

Apple

$172.79

-5.05 (-2.84%)

LPL

LG Display

$11.71

-0.325 (-2.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

PF

Pinnacle Foods

$55.20

-1.48 (-2.61%)

, CAG

Conagra Brands

$36.64

-0.52 (-1.40%)

06:28
04/20/18
04/20
06:28
04/20/18
06:28
Recommendations
Pinnacle Foods, Conagra Brands, Kraft Heinz analyst commentary  »

Pinnacle Foods is a…

PF

Pinnacle Foods

$55.20

-1.48 (-2.61%)

CAG

Conagra Brands

$36.64

-0.52 (-1.40%)

KHC

Kraft Heinz

$59.71

-1.09 (-1.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

AAPL

Apple

$172.79

-5.05 (-2.84%)

06:27
04/20/18
04/20
06:27
04/20/18
06:27
Periodicals
Apple chief denies speculation the company could merge iOS, MacOS, SMH reports »

Amid rumors that Apple is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

LONE

Lonestar Resources

$4.95

0.04 (0.81%)

06:25
04/20/18
04/20
06:25
04/20/18
06:25
Syndicate
Breaking Syndicate news story on Lonestar Resources »

Lonestar Resources files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

ELF

e.l.f. Beauty

$18.93

-0.445 (-2.30%)

06:23
04/20/18
04/20
06:23
04/20/18
06:23
Recommendations
e.l.f. Beauty analyst commentary  »

e.l.f. Beauty has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

GM

General Motors

$37.77

-1.165 (-2.99%)

06:21
04/20/18
04/20
06:21
04/20/18
06:21
Periodicals
GM Korea, union enter fresh round of talks to stave off bankruptcy, Reuters says »

General Motors'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

VIVHY

Vivendi

06:20
04/20/18
04/20
06:20
04/20/18
06:20
Periodicals
Vivendi weighs listing of Universal Music Group, NY Post says »

Vivendi chief Arnaud de…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$85.65

-15.86 (-15.62%)

06:19
04/20/18
04/20
06:19
04/20/18
06:19
Downgrade
Philip Morris rating change  »

Philip Morris downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

UGI

UGI Corporation

$45.80

0.045 (0.10%)

06:19
04/20/18
04/20
06:19
04/20/18
06:19
Upgrade
UGI Corporation rating change  »

UGI Corporation upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 20

    May

DB

Deutsche Bank

$14.46

0.015 (0.10%)

, DBOEY

Deutsche Boerse

06:15
04/20/18
04/20
06:15
04/20/18
06:15
Periodicals
Deutsche Bank blames 'operational error' for accidental EUR28B transfer, FT says »

Deutsche Bank (DB) has…

DB

Deutsche Bank

$14.46

0.015 (0.10%)

DBOEY

Deutsche Boerse

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

SWK

Stanley Black & Decker

$154.68

-2.715 (-1.73%)

06:12
04/20/18
04/20
06:12
04/20/18
06:12
Hot Stocks
Stanley Black & Decker executed equity derivative deal to lock buyback pricing »

During Q1, Stanley Black…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 04

    Jun

PG

Procter & Gamble

$74.98

-2.4928 (-3.22%)

06:12
04/20/18
04/20
06:12
04/20/18
06:12
Downgrade
Procter & Gamble rating change  »

Procter & Gamble…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

SWK

Stanley Black & Decker

$154.68

-2.715 (-1.73%)

06:08
04/20/18
04/20
06:08
04/20/18
06:08
Hot Stocks
Stanley Black & Decker CEO say Q1 organic growth up 4% »

Stanley Black &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 04

    Jun

MAT

Mattel

$13.44

-0.45 (-3.24%)

06:08
04/20/18
04/20
06:08
04/20/18
06:08
Hot Stocks
Ancestry names Margo Georgiadis as CEO »

Ancestry announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

CLNE

Clean Energy

$1.64

-0.015 (-0.91%)

06:07
04/20/18
04/20
06:07
04/20/18
06:07
Hot Stocks
Clean Energy to build three CNG stations in Ontario for Union Energy Solutions »

Clean Energy Fuels has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADMS

Adamas Pharmaceuticals

$27.68

1.82 (7.04%)

06:06
04/20/18
04/20
06:06
04/20/18
06:06
Recommendations
Adamas Pharmaceuticals analyst commentary  »

Adamas positioned for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 25

    Apr

  • 12

    Jun

SWK

Stanley Black & Decker

$154.68

-2.715 (-1.73%)

06:06
04/20/18
04/20
06:06
04/20/18
06:06
Earnings
Stanley Black & Decker backs FY18 adj. EPS view of $8.30-$8.50, consensus $8.43 »

Management is revising…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 04

    Jun

ROP

Roper Technologies

$279.93

0.195 (0.07%)

06:05
04/20/18
04/20
06:05
04/20/18
06:05
Earnings
Breaking Earnings news story on Roper Technologies »

Roper Technologies sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Apr

  • 16

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.